Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443557 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TSHRSMN1; SMN2CASP1TP53 | |
| SCHEMBL1712905 | 0.81 | KMT2A (0.41) | ALDH1A1TSHRSMN1; SMN2CASP1CA1 | |
| SCHEMBL441463 | 0.81 | MAPK1 (0.33) | ALDH1A1SMN1; SMN2KDM4EMAPTMEN1 | |
| SCHEMBL490677 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TSHRSMN1; SMN2TP53ALOX15 | |
| SCHEMBL28168434 | 0.79 | AKR1C3 (0.46) | ALDH1A1ALOX15NR4A1AKR1C3KDM4E | |
| SCHEMBL724327 | 0.78 | GABRA1 (0.31) | — | |
| SCHEMBL4322089 | 0.76 | MAPK1 (0.32) | ALDH1A1SMN1; SMN2AKR1C2AKR1C1HTT | |
| SCHEMBL1713036 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TSHRSMN1; SMN2TP53KDM4E | |
| SCHEMBL1712644 | 0.76 | ABL1 (0.42) | ALDH1A1TSHRSMN1; SMN2CASP1CA1 | |
| SCHEMBL1266916 | 0.76 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2CASP1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110330465-A | Hydrazone amide derivatives and its application in preparation prevention and treatment alopecia agent | 深圳市三启药物开发有限公司 | 2019-10-15 | — | — | CN | claimed |
| CN-110229118-A | Hydrazone amide derivatives and its preparing the application in osteosporosis resistant medicament | 深圳市三启药物开发有限公司 | 2019-09-13 | — | — | CN | claimed |
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2019-07-25 | — | — | US | claimed |
| US-9682955-B2 | Quinazoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | claimed |
| US-9682940-B2 | Indazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | claimed |
| WO-2017034872-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | claimed |
| US-20170057925-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | claimed |
| WO-2016040081-A1 | QUINAZOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | claimed |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-10 | — | — | US | claimed |
| US-9139546-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2015-09-22 | — | — | US | claimed |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2010-05-27 | — | — | US | claimed |
| US-7696200-B2 | Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | claimed |
| CN-101631781-A | Improved preparation method of ethyl (S) -2-ethoxy-4- [ N- [ 1- (2-piperidinophenyl) -3-methyl-1-butyl ] aminocarbonylmethyl ] benzoate and application thereof in preparation of repaglinide | ACTAVIS GROUP PTC EHF | 2010-01-20 | — | — | CN | claimed |
| EP-2131655-A2 | TRI-ARYL/HETEROAROMATIC CANNABINOIDS AND USE THEREOF | The University of Tennessee Research Foundation (US) | 2009-12-16 | — | — | EP | claimed |
| CN-101379044-A | Heterobicyclic sulfonamide derivatives for the treatment of diabetes | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | claimed |
| EP-1996563-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-09-25 | — | — | US | claimed |
| WO-2008109027-A2 | TRI-ARYL/HETEROAROAROMATIC CANNABINOIDS AND USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2008-09-12 | — | — | WO | claimed |
| WO-2007093507-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | ALDH1A1 324/4885TSHR 2480/4885SMN1; SMN2 2801/4885 |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | CNR1, CNR2, OPRM1 | ALDH1A1 1887/4885TSHR 373/4885SMN1; SMN2 4721/4885 |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | ALDH1A1 324/4885TSHR 2480/4885SMN1; SMN2 2801/4885 |
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | ALDH1A1 1493/4885TSHR 3195/4885SMN1; SMN2 2129/4885 |
| US-20170057925-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | ALDH1A1 689/4885TSHR 703/4885SMN1; SMN2 3315/4885 |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | CNR1, CNR2, GPR119 | ALDH1A1 1414/4885TSHR 874/4885SMN1; SMN2 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.